DAFTAR PUSTAKA

Aljabeiti, A., Salahuddin, R., Tolar, M., & Tolarova, M. (2017). Association of TGFβ3 variants with Nonsyndromic Cleft Lip and Palate in Guatemalan Population. *J Den Craniofac Res*, *2*(1), 9.

Amoaku, W., Chakravarthy, U., Gale, R., Gavin, M., Ghanchi, F., Gibson, J., Harding, S., Johnston, R., Kelly, S., & Lotery, A. (2015). Defining response to anti-VEGF therapies in neovascular AMD. *Eye*, *29*(6), 721-731.

Armstrong, R. A., & Mousavi, M. (2015). Overview of risk factors for age-related macular degeneration (AMD). *Journal of Stem Cells*, *10*(3), 171.

Balikova, I., Postelmans, L., Pasteels, B., Coquelet, P., Catherine, J., Efendic, A., Hosoda, Y., Miyake, M., Yamashiro, K., & Thienpont, B. (2019). Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degeneration. *BMJ open ophthalmology*, *4*(1), e000273.

Blasiak, J. (2020). Senescence in the pathogenesis of age-related macular degeneration. *Cellular and Molecular Life Sciences*, *77*, 789-805.

Caspers, S., Abramowicz, S., Pasteels, B., & Postelmans, L. (2024). Smoking and short-term response to intravitreal anti-Vascular Endothelial Growth Factor injections in neovascular age-related macular degeneration. *Journal Français d'Ophtalmologie*, *47*(1), 103955.

Chen, G., Tzekov, R., Li, W., Jiang, F., Mao, S., & Tong, Y. (2015). Pharmacogenetics of complement factor H Y402H polymorphism and treatment of neovascular AMD with anti-VEGF agents: a meta-analysis. *Scientific reports*, *5*(1), 14517.

Chen, H., Yu, K.-D., & Xu, G.-Z. (2012). Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis.

Chew, E. Y., & Swaroop, A. (2021). *Age-related Macular Degeneration: From Clinic to Genes and Back to Patient Management*. Springer.

Coleman, H. R., Chan, C.-C., Ferris III, F. L., & Chew, E. Y. (2008). Age-related macular degeneration. *The Lancet*, *372*(9652), 1835-1845.

Cook, H., Patel, P., & Tufail, A. (2008). Age-related macular degeneration: diagnosis and management. *British medical bulletin*, *85*(1), 127-149.

Deng, Y., Qiao, L., Du, M., Qu, C., Wan, L., Li, J., & Huang, L. (2022). Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. *Genes & diseases*, *9*(1), 62-79.

Fritsche, L. G., Fariss, R. N., Stambolian, D., Abecasis, G. R., Curcio, C. A., & Swaroop, A. (2014). Age-related macular degeneration: genetics and biology coming together. *Annual review of genomics and human genetics*, *15*, 151.

Garcia-Garcia, J., Usategui-Martin, R., Sanabria, M. R., Fernandez-Perez, E., Telleria, J. J., & Coco-Martin, R. M. (2022). Pathophysiology of age-related macular

degeneration: implications for treatment. *Ophthalmic Research*, *65*(6), 615-636.

Gasperini, J. L., Fawzi, A. A., Khondkaryan, A., Lam, L., Chong, L. P., Eliott, D., Walsh, A. C., Hwang, J., & Sadda, S. R. (2012). Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. *British Journal of Ophthalmology*, *96*(1), 14-20.

Ghasemi, H., Ghazanfari, T., Yaraee, R., Faghihzadeh, S., & Hassan, Z. M. (2011). Roles of IL-8 in ocular inflammations: a review. *Ocular immunology and inflammation*, *19*(6), 401-412.

Goverdhan, S. V., Ennis, S., Hannan, S., Madhusudhana, K., Cree, A., Luff, A., & Lotery, A. J. (2008). Interleukin-8 promoter polymorphism− 251A/T is a risk factor for age-related macular degeneration. *British Journal of Ophthalmology*, *92*(4), 537-540.

Group, C. R. (2011). Ranibizumab and bevacizumab for neovascular age-related macular degeneration. *New England Journal of Medicine*, *364*(20), 1897-1908.

Hautamäki, A., Kivioja, J., Vavuli, S., Kakko, S., Savolainen, E.-R., Savolainen, M. J., Liinamaa, M. J., Seitsonen, S., Onkamo, P., & Järvelä, I. (2013). Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration. *Retina*, *33*(9), 1815-1827.

Jonas, J., Spandau, U., & Schlichtenbrede, F. (2008). Short-term complications of intravitreal injections of triamcinolone and bevacizumab. *Eye*, *22*(4), 590-591.

Kaiser, P. K., Wykoff, C. C., Singh, R. P., Khanani, A. M., Do, D. V., Patel, H., & Patel, N. (2021). Retinal fluid and thickness as measures of disease activity in neovascular age-related macular degeneration. *Retina*, *41*(8), 1579-1586.

Karki, R., Pandya, D., Elston, R. C., & Ferlini, C. (2015). Defining "mutation" and "polymorphism" in the era of personal genomics. *BMC medical genomics*, *8*(1), 1-7.

Kaya, C., Zandi, S., Pfister, I. B., Gerhardt, C., & Garweg, J. G. (2019). Adding a corticosteroid or switching to another anti-VEGF in insufficiently responsive wet age-related macular degeneration. *Clinical Ophthalmology*, 2403-2409.

Kozlowski, M. R. (2012). RPE cell senescence: a key contributor to age-related macular degeneration. *Medical hypotheses*, *78*(4), 505-510.

Kuroda, Y., Yamashiro, K., Miyake, M., Yoshikawa, M., Nakanishi, H., Oishi, A., Tamura, H., Ooto, S., Tsujikawa, A., & Yoshimura, N. (2015). Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. *Ophthalmology*, *122*(11), 2303-2310.

Łądkowska, J., Gawęcki, M., & Szołkiewicz, M. (2021). Efficacy of anti-vascular endothelial growth factor treatent in neovascular age-related macular degeneration and systemic cardiovascular risk factors. *Journal of clinical medicine*, *10*(19), 4595.

56

Lee, J., Moon, B. G., Cho, A. R., & Yoon, Y. H. (2016). Optical coherence tomography angiography of DME and its association with anti-VEGF treatment response. *Ophthalmology*, *123*(11), 2368-2375.

Lee, K. S., Lin, S., Copland, D. A., Dick, A. D., & Liu, J. (2021). Cellular senescence in the aging retina and developments of senotherapies for age-related macular degeneration. *Journal of Neuroinflammation*, *18*(1), 1-17.

Lerner, K. L. (2002). Wild Type. *(Draft Copy) Originally published in: Lerner, KL and Lerner, BW. World of Genetics. Thomson/ Gale*.

Metrangolo, C., Donati, S., Mazzola, M., Fontanel, L., Messina, W., D'alterio, G., Rubino, M., Radice, P., Premi, E., & Azzolini, C. (2021). OCT Biomarkers in Neovascular Age-Related Macular Degeneration: A Narrative Review. *Journal of Ophthalmology*, *2021*(1), 9994098.

Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018). Age-related macular degeneration. *The Lancet*, *392*(10153), 1147-1159.

Moutray, T., & Chakravarthy, U. (2011). Age-related macular degeneration: current treatment and future options. *Therapeutic advances in chronic disease*, *2*(5), 325-331.

Ong, B., & Ah-Fat, F. (2016). Age-related macular degeneration. *British Journal of Hospital Medicine*, *77*(2), C18-C21.

Pennington, K. L., & DeAngelis, M. M. (2016). Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. *Eye and vision*, *3*(1), 1-20.

Remington, L. A., & Goodwin, D. (2021). *Clinical Anatomy and Physiology of the Visual System E-Book*. Elsevier Health Sciences.

Reznicek, L., Muhr, J., Ulbig, M., Kampik, A., Mayer, W. J., Haritoglou, C., Neubauer, A., & Wolf, A. (2014). Visual acuity and central retinal thickness: fulfilment of retreatment criteria for recurrent neovascular AMD in routine clinical care. *British Journal of Ophthalmology*, *98*(10), 1333-1337.

Roshanipour, N., Shahriyari, E., Ghaffari Laleh, M., Vahedi, L., Mirjand Gerami, S., & Khamaneh, A. (2021). Associations of TLR4 and IL-8 genes polymorphisms with age-related macular degeneration (AMD): a systematic review and meta-analysis. *Ophthalmic Genetics*, *42*(6), 641-649.

Schiefelbein, J., Müller, M., Kern, C., Herold, T., Liegl, R., Fasler, K., Jeliazkova, D., Priglinger, S., & Kortuem, K. U. (2020). Gender-related differences in patients treated with intravitreal anti-vascular endothelial growth factor medication for diabetic macular oedema. *European Journal of Ophthalmology*, *30*(6), 1410-1417.

Sharma, D., Zachary, I., & Jia, H. (2023). Mechanisms of acquired resistance to anti-VEGF therapy for neovascular eye diseases. *Investigative ophthalmology & visual science*, *64*(5), 28-28.

Stahl, A. (2020). The diagnosis and treatment of age-related macular degeneration. *Deutsches Ärzteblatt International*, *117*(29-30), 513.

Thomsen, A. K., Krogh Nielsen, M., Liisborg, C., & Sørensen, T. L. (2024). Interleukin-8 Promoter Polymorphism− 251 A/T and Treatment Response in Neovascular Age-related Macular Degeneration. *Clinical Ophthalmology*, 537-543.

Tsai, Y.-Y., Lin, J.-M., Wan, L., Lin, H.-J., Tsai, Y., Lee, C.-C., Tsai, C.-H., Tsai, F.-J., & Tseng, S.-H. (2008). Interleukin gene polymorphisms in age-related macular degeneration. *Investigative ophthalmology & visual science*, *49*(2), 693-698.

Wu, M., Xiong, H., Xu, Y., Xiong, X., Zou, H., Zheng, M., Wang, X., & Zhou, X. (2017). Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis. *British Journal of Ophthalmology*, *101*(7), 976-984.

Yang, S., Zhao, J., & Sun, X. (2016). Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. *Drug design, development and therapy*, *10*, 1857.

Zhou, J., Ma, H., Zhou, X., Wang, Q., Li, W., Luo, S., Cai, C., Li, Z., & Liu, D. (2022). Two-Week Central Macular Thickness Reduction Rate> 37% Predicts the Long-Term Efficacy of Anti-vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Retinal Vein Occlusion. *Frontiers in Medicine*, *9*.